Abstract 1096
Background
OncotypeDX (ODX®) can enhance prediction of breast cancer recurrence, guiding adjuvant treatment options. However, the opportunity to access this test is not always possible. The aim of this study is to investigate the correlation between phenotypical tumor characteristics, quantitative classical immunohistochemistry (IHC) and recurrent score (RS) resulting from ODX®.
Methods
All breast cancer patients who underwent ODX® between 2014 and 2018 were retrospectively included in the study. The data selected for analysis were age, menopausal status, pathological and IHC features. IHC was performed with standardized quantitative methods. Dataset was split into two subsets (70% for training and 30% for internal validation). Logistic models were built with statistically significant features for predicting RS ≤ 25 or ≤ 20. An external validation set, provided by another center, was used to test reliability of prediction models.
Results
The internal dataset included 407 patients (Table) who underwent ODX®. Mean age was 53.7 (31-80) and 222 patients (54.55%) were > 50 years old. ODX® results showed: 67 patients (16.6%) between 0-10, 272 patients between 11-25 (66.8%) and 68 pts > 26 (16.6%). At the logistic regression analysis, RS score was significantly associated with ER (p = 0.004), PgR (p < 0.001), and Ki67% (p < 0.001) with the threshold equal to 25. Above patients with RS ≤ 25, the generalized linear regression resulted in a well calibrated model with an AUC of 92.2% (sensitivity 84.2%; specificity 80.1%). External validation set included 180 patients and confirmed the model performance with an AUC of 82.3% and good calibration. A nomogram predicting RS score ≤25 was generated.Table:
261P Tumor characteristics training set + internal test set
Training + internal test set – Tumor characteristics | ||
---|---|---|
Histological subtype classification | Invasive Ductal Carcinoma | 318 pts (78,1%) |
Invasive Lobular Carcinoma | 47 pts (11,5%) | |
Other | 42 pts (10,3%) | |
Grading | 1 | 28 pts (6.8%) |
2 | 268 pts (65,8%) | |
3 | 111 pts (27,3%) | |
pT | 1a | 3 pts (0,7%) |
1b | 38 pts (9,3%) | |
1c | 216 pts (53,1%) | |
2 | 143 pts (35,1%) | |
3 | 6 pts (1,5%) | |
4 | 1 pt (0,3%) | |
pN | 0 | 233 pts (57,2%) |
0i+ | 12 pts (3%) | |
1mic | 43 pts (10,6%) | |
1 | 108 pts (26,5%) | |
NA | 11 pts (2,7%) | |
Mean T diameter [cm] | 1.9 (Range 0,2-8,5) | |
Mean Sentinel Lymph Node (SLN) diameter [mm] | 1.7 (Range 0-40) | |
Mean Axillary Lymph Node (ALN) diameter [mm] | 0.8 (Range 0-25) | |
Mean N Ratio | 0.14 (0.00 – 1.00) | |
SLN involvement [n° of nodes] | 0 | 261 pts (64,1%) |
1 | 112 pts (27,5%) | |
2 | 24 pts (5,8%) | |
3 | 1 pt (0,2%) | |
NA | 9 pts (2,2%) | |
ALN involvement [n° of nodes] | 0 | 338 pts (83%) |
0i+ | 4 pts (1%) | |
1mic | 3 pts (0,7%) | |
1 | 31 pts (7,6%) | |
2 | 8 pts (2%) | |
3 | 5 pts (1,2%) | |
5 | 1 pt (0,2%) | |
NA | 17 pts (4,1%) | |
Multifocality | Yes | 97 pts (23,8%) |
No | 300 pts (73,7%) | |
NA | 10 pts (2.5%) | |
Multicentricity | Yes | 20 pts (4,9%) |
No | 376 pts (92,4%) | |
NA | 11 pts (2,7%) | |
PVI | Absent | 242 pts (59,4%) |
Focal | 51 pts (12,5%) | |
Moderate | 32 pts (7,8%) | |
Massive | 59 pts (14,5%) | |
NA | 23 pts (5,6%) | |
Mean ER expression | 87,9% (Range 1-100) | |
Mean PgR expression | 62.2% (Range 0-100) | |
Mean AR expression | 7.7% (Range 0-90) | |
Mean Ki67% expression | 29.8% (Range 0-90) | |
Her2 Expression | 0 | 187 pts (46%) |
1 | 112 pts (27,5%) | |
2 | 104 pts (25,5%) | |
NA | 4 pts (0,9%) | |
Fluorescence in situ hybridization (FISH) for HER-2 | Not determined | 300 pts (73,7%) |
Not amplificated | 100 pts (23,7%) | |
Undetermined | 1 pt (0,2%) | |
Equivocal | 1 pt (0,2%) |
Conclusions
Quantitative IHC presents a good correlation with RS score in patients with RS ≤ 25, also in external validation set. A nomogram for physician that enhances a cost/effectiveness clinical approach practice has been developed. Prospective clinical application will be tested in further studies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fabio Marazzi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4331 - STING Agonist, ADU-S100, Yields Potent Antitumor Activity and Therapeutically Favorable Immune Profile in an Esophageal Adenocarcinoma Model
Presenter: Ali Zaidi
Session: Poster Display session 2
Resources:
Abstract
1770 - Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study
Presenter: Willemieke Dijksterhuis
Session: Poster Display session 2
Resources:
Abstract
3755 - A new docetaxel (DOC)-based triplet regimen does not improve the outcome of metastatic (M) or locally advanced (LA) gastric cancer (GC) as compared with an epirubicin (EPI) standard triplet regimen: a GISCAD trial.
Presenter: Roberto Labianca
Session: Poster Display session 2
Resources:
Abstract
2439 - The analysis of T cell subsets and clinical efficacy of immune checkpoint blockades in patients with advanced gastric cancer using multiplex immunohistochemistry
Presenter: Tae-yong Kim
Session: Poster Display session 2
Resources:
Abstract
2211 - First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma.
Presenter: Yelena Janjigian
Session: Poster Display session 2
Resources:
Abstract
3046 - Monitoring patient-specific mutation in ctDNA and CTC for tumor response evaluation after neoadjuvant chemotherapy in locally advanced gastric cancer (NCT03425058)
Presenter: Tao Fu
Session: Poster Display session 2
Resources:
Abstract
4628 - Gastric cancer screening in BRCA 2 gene mutation carriers: should it be recommended?
Presenter: Inês Oliveira
Session: Poster Display session 2
Resources:
Abstract
2127 - Interim analysis of an observational/translational study for nivolumab treatment in advanced gastric cancer: JACCRO GC-08 (DELIVER trial)
Presenter: Yu Sunakawa
Session: Poster Display session 2
Resources:
Abstract
2264 - Prediction of S-1 adjuvant chemotherapy efficacy in Stage II/III gastric cancer treatment based on comprehensive gene expression analysis
Presenter: Masanori Terashima
Session: Poster Display session 2
Resources:
Abstract
2444 - Assessing the clinical utility of circulating tumour DNA through longitudinal liquid biopsy sampling in Oesophageal adenocarcinoma
Presenter: Emma Ococks
Session: Poster Display session 2
Resources:
Abstract